By MARY SHEDDEN | The Tampa Tribune
Published: June 22, 2009
Individuals living with foot and leg ulcers are being sought for a first-phase research study for a new medication.
The focus of the study, peripheral artery disease, is a circulatory condition that narrows arteries and, as a result, restricts blood flow. People with high cholesterol, diabetes and high blood pressure are at high risk.
Of particular concern are persons at the stage called "critical limb ischemia," where the disease starts to starve body tissues of blood, creates ulcers and increases the risk of amputation.
Local researchers will be testing a new medication that might promote blood vessel growth. Qualified participants must be 50 years or older and diagnosed at the critical limb ischemia stage. Other criteria also apply.
This research is a phase-one study, the first of three lengthy rounds of research necessary for a drug to be considered by the Food and Drug Administration.
Recruitment for the study ends Friday. For more information about eligibility, call (888) 853-4656 or visit www.tamarisstudy.com.
Tuesday, June 23, 2009
Sunday, June 14, 2009
What is Leg Ischemia?
Leg ischemia is the condition when the leg does not receive the necessary amount of oxygen (via the blood circulation) that is required for the activity underway.
How Do I Know if I Have Leg Ischemia?
Ischemia of the lower extremities will manifest itself in many different ways ranging from asymptomatic (simply the presence of a blockage) to gangrene of the leg or a part of it. Quite often a patient will have an asymptomatic blockage (one that they do not know is there) that is manifested simply by an absent pulse in the foot, behind the knee or in the groin or an abnormal angiogram that is usually done at the time that a cardiac catheterization (heart catheterization) is performed. A person will have no symptoms referable to this blockage and will only know of the abnormality because their physician informs them of such! This is generally referred to as Fontaine’s Class I.
~ The Cardiovasular Care Group~
How Do I Know if I Have Leg Ischemia?
Ischemia of the lower extremities will manifest itself in many different ways ranging from asymptomatic (simply the presence of a blockage) to gangrene of the leg or a part of it. Quite often a patient will have an asymptomatic blockage (one that they do not know is there) that is manifested simply by an absent pulse in the foot, behind the knee or in the groin or an abnormal angiogram that is usually done at the time that a cardiac catheterization (heart catheterization) is performed. A person will have no symptoms referable to this blockage and will only know of the abnormality because their physician informs them of such! This is generally referred to as Fontaine’s Class I.
~ The Cardiovasular Care Group~
Wednesday, June 3, 2009
Foot Screenings...How important are they?
There are no screening protocols in hemodialysis centers to identify the problem earlier on. As a result preventive strategies to reduce morbidity and mortality related to this issue remains unaddressed. The magnitude of this problem is unrealized until you add to the equation that majority of hemodilaysis patients are diabetics as well. As a result there remains a significant issue of lower extremity amputations in hemodialysis patients. Overall 40% of patients in United States starting chronic dialysis count diabetes mellitus as the primary cause of renal failure, making it the number one cause of CKD (Berman et al, 2001). Patients with diabetes and chronic renal disease frequently present with a combination of the devastations of diabetes including: nephropathy, retinopathy, and vasculopathy. The main focus of the care of these patients has been on the target organs like heart and kidneys. Therefore, early risk factors for diabetic foot complications may be disregarded, and this may lead to amputation--a failure for both the patient and physician. Diabetic foot complications, including amputation, add significantly to the morbidity and mortality of the patient with diabetes and CKD. However, of all the long-term complications of diabetes, foot complications may be the most preventable. In the United States, diabetes is the cause of 50% of nontraumatic lower extremity amputations and is increasing annually (Levin, 2002). The prevalence of lower extremity amputation for patients with diabetes and CKD is much greater than those without CKD. The rate of lower limb amputation for the population at large increased during a recent 4-year period from 4.8 to 6.2 /100 persons. During the same time frame, this rate of lower extremity amputation rose from 11.8 to 13.8/100 among persons with CKD attributed to diabetic nephropathy. The rate for patients with diabetes and CKD was 10 times greater than the diabetic population at large (Eggers, Gohdes, & Pugh et al, 1999). The cost of treating patients with diabetes is astronomical both financially and in terms of quality of life. The loss of a lower extremity or even part of a lower extremity greatly impacts quality of life.
by Zahid Ahmad, M.D.
University of Oklahoma
Asst. Professor of Medicine – Interventional Nephrology
Section of Nephrology & Hypertention
by Zahid Ahmad, M.D.
University of Oklahoma
Asst. Professor of Medicine – Interventional Nephrology
Section of Nephrology & Hypertention
Thursday, May 21, 2009
Peripheral Arterial Disease of the Legs - Overview
What is peripheral arterial disease of the legs?
Peripheral arterial disease (PAD) is narrowing or blockage of arteries that results in poor blood flow to your arms and legs. When you walk or exercise, your leg muscles do not get enough blood and you can get painful cramps.
Peripheral arterial disease is also called peripheral vascular disease. This topic focuses on peripheral arterial disease of the legs, the area where it is most common.
What causes PAD?
The most common cause is the buildup of plaque on the inside of arteries. Plaque is made of extra cholesterol, calcium, and other material in your blood. Over time, plaque builds up along the inner walls of the arteries, including those that supply blood to your legs.
If plaque builds up in your arteries, there is less room for blood to flow. Every part of your body needs blood that is rich in oxygen. But plaque buildup prevents that blood from flowing freely and starves the muscles and other tissues in the lower body.
This process of plaque buildup usually happens at the same time throughout the body. It is called atherosclerosis or hardening of the arteries. If you have this problem in your legs, you most likely will have it in the arteries that supply blood to your heart and brain. This increases your chance of having a heart attack or stroke.
Plaque builds up bit by bit over a lifetime, but symptoms often do not start until after age 65. High cholesterol, high blood pressure, and smoking make you more likely to get atherosclerosis and peripheral arterial disease.
What are the symptoms?
Many people who have PAD do not have any symptoms.
But if you do have symptoms, you may have a tight, aching, or squeezing pain in the calf, thigh, or buttock. This pain, called intermittent claudication, usually happens after you have walked a certain distance. For example, your pain may always start after you have walked a block or two or after a few minutes. The pain goes away if you stop walking. As PAD gets worse, you may have pain in your foot or toe when you are not walking.
How is PAD diagnosed?
Your doctor will talk with you about your symptoms and past health and will do a physical exam. During the exam, your doctor will check your pulse at your groin, behind your knee, on the inner ankle, and on the top of your foot. Your pulse shows the strength of blood flow. An absent or weak pulse in these spots is a sign of PAD. Your doctor may also look at the color of your foot when it is higher than the level of your heart and after exercise. The color of your foot can be a clue to whether enough blood is getting through your arteries.
You will likely have a test that compares the blood pressure in your legs with the blood pressure in your arms. This test is called an ankle-brachial index. A test called an arterial Doppler ultrasound may be done to check the blood flow in your arteries.
Blood tests to check your cholesterol and blood sugar can tell whether you may have other problems related to PAD, such as high cholesterol and diabetes.
How is it treated?
One of the most important things you can do for PAD is to quit smoking. If you need help quitting, talk to your doctor about programs and medicines that can help you stop. These can increase your chances of quitting forever.
There are also products that gradually wean you off nicotine. These include nicotine patches, chewing gums, nasal sprays, inhalers, and lozenges. These treatments help people have better success in the long term.1
Your doctor may tell you to eat healthy foods and to get more exercise. You may need to take aspirin and medicines to lower your cholesterol and control your symptoms. If you have diabetes, you will need to carefully control your blood sugar.
Combined, these measures can help control your symptoms and reverse the blockage of your arteries. Keeping your arteries open can help lower your risk of heart attack and stroke. And it may also improve the quality and length of your life.
If your leg pain does not get better after a few months of treatment, your doctor may prescribe a medicine called cilostazol (Pletal) to help with the pain when you walk.
If you still do not get better, you may need a procedure called angioplasty or bypass surgery to open narrowed arteries or reroute blood flow around them. These treatments are usually used for severe peripheral arterial disease.
In rare cases, advanced PAD can cause tissues in the leg or foot to die because they do not get enough oxygen as a result of poor blood flow. If this happens, part of the leg or foot must be removed (amputated). This is more common in people who also have diabetes.
Peripheral arterial disease (PAD) is narrowing or blockage of arteries that results in poor blood flow to your arms and legs. When you walk or exercise, your leg muscles do not get enough blood and you can get painful cramps.
Peripheral arterial disease is also called peripheral vascular disease. This topic focuses on peripheral arterial disease of the legs, the area where it is most common.
What causes PAD?
The most common cause is the buildup of plaque on the inside of arteries. Plaque is made of extra cholesterol, calcium, and other material in your blood. Over time, plaque builds up along the inner walls of the arteries, including those that supply blood to your legs.
If plaque builds up in your arteries, there is less room for blood to flow. Every part of your body needs blood that is rich in oxygen. But plaque buildup prevents that blood from flowing freely and starves the muscles and other tissues in the lower body.
This process of plaque buildup usually happens at the same time throughout the body. It is called atherosclerosis or hardening of the arteries. If you have this problem in your legs, you most likely will have it in the arteries that supply blood to your heart and brain. This increases your chance of having a heart attack or stroke.
Plaque builds up bit by bit over a lifetime, but symptoms often do not start until after age 65. High cholesterol, high blood pressure, and smoking make you more likely to get atherosclerosis and peripheral arterial disease.
What are the symptoms?
Many people who have PAD do not have any symptoms.
But if you do have symptoms, you may have a tight, aching, or squeezing pain in the calf, thigh, or buttock. This pain, called intermittent claudication, usually happens after you have walked a certain distance. For example, your pain may always start after you have walked a block or two or after a few minutes. The pain goes away if you stop walking. As PAD gets worse, you may have pain in your foot or toe when you are not walking.
How is PAD diagnosed?
Your doctor will talk with you about your symptoms and past health and will do a physical exam. During the exam, your doctor will check your pulse at your groin, behind your knee, on the inner ankle, and on the top of your foot. Your pulse shows the strength of blood flow. An absent or weak pulse in these spots is a sign of PAD. Your doctor may also look at the color of your foot when it is higher than the level of your heart and after exercise. The color of your foot can be a clue to whether enough blood is getting through your arteries.
You will likely have a test that compares the blood pressure in your legs with the blood pressure in your arms. This test is called an ankle-brachial index. A test called an arterial Doppler ultrasound may be done to check the blood flow in your arteries.
Blood tests to check your cholesterol and blood sugar can tell whether you may have other problems related to PAD, such as high cholesterol and diabetes.
How is it treated?
One of the most important things you can do for PAD is to quit smoking. If you need help quitting, talk to your doctor about programs and medicines that can help you stop. These can increase your chances of quitting forever.
There are also products that gradually wean you off nicotine. These include nicotine patches, chewing gums, nasal sprays, inhalers, and lozenges. These treatments help people have better success in the long term.1
Your doctor may tell you to eat healthy foods and to get more exercise. You may need to take aspirin and medicines to lower your cholesterol and control your symptoms. If you have diabetes, you will need to carefully control your blood sugar.
Combined, these measures can help control your symptoms and reverse the blockage of your arteries. Keeping your arteries open can help lower your risk of heart attack and stroke. And it may also improve the quality and length of your life.
If your leg pain does not get better after a few months of treatment, your doctor may prescribe a medicine called cilostazol (Pletal) to help with the pain when you walk.
If you still do not get better, you may need a procedure called angioplasty or bypass surgery to open narrowed arteries or reroute blood flow around them. These treatments are usually used for severe peripheral arterial disease.
In rare cases, advanced PAD can cause tissues in the leg or foot to die because they do not get enough oxygen as a result of poor blood flow. If this happens, part of the leg or foot must be removed (amputated). This is more common in people who also have diabetes.
Wednesday, May 20, 2009
Pervasis Therapeutics Presents Promising Preclinical Data for its Minimally Invasive Cell Therapy
Study Findings Show Treatment with PVS-10200 Following Angioplasty and Stent Placement for Peripheral Artery Disease in a Porcine Model Reduces Intimal Area and Enhances Vascular Repair
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active cellular therapies to treat vascular and other serious diseases, today announced new preclinical data for the Company’s minimally invasive cell therapy, PVS-10200. Results from the preclinical study found that treatment with PVS-10200 (tissue engineered allogeneic endothelial cells) following an intervention for peripheral arterial disease (PAD) resulted in a statistically significant increased lumen area, reduced intimal area, and decreased occlusion compared to control. These data were presented in an oral presentation today at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions in Barcelona, Spain.
In this preclinical study, researchers evaluated treatment with ultrasound-guided percutaneous (needle delivered) administration of PVS-10200 to the outside of porcine (pig) femoral arteries immediately following angioplasty and stent placement. Animals in the control group received angioplasty and stents with no further treatment (sham standard of care control). A third group was treated with injection of matrix alone. A total of 36 femoral arteries were evaluated in the study and evaluations were conducted at 30 and 90 days following treatment. At 90 days, PVS-10200 treated arteries had significantly decreased intimal area (3.3 ± 0.4 mm²) compared to control (6.2 ± 0.5 mm², P<0.05) and increased lumen area (20.4 ± 0.7 mm²) compared to control (16.1 ± 0.9 mm² P<0.05). After 90 days, PVS-10200 treated arteries had a 50 percent decrease in percent occlusion compared to sham control (P<0.05). Treatment with the gelatin matrix alone did not differ significantly from the sham control.
“Restenosis, or narrowing of the arteries, following procedural treatment for PAD occurs frequently and is associated with a number of vascular complications and re-interventions,” added Helen M. Nugent, Ph.D., co-founder and vice president, research and development at Pervasis and co-author of the study. “PVS-10200 provides endothelial-based factors to the injured artery, which regulates the inflammatory response within the blood vessel and promotes natural healing. Results from this study indicate that PVS-10200 may offer a novel therapeutic option that can effectively reduce the intimal area and reduce occlusion, and therefore limit restenosis following treatment for PAD.”
“We are pleased to present this compelling preclinical data for PVS-10200,” stated Frederic Chereau, president and chief executive officer of Pervasis Therapeutics. “Treatment with drug-eluting stents has shown no benefit within the peripheral vasculature. There continues to be a significant unmet medical need and a large market potential for new therapies to effectively address common complications related to vascular intervention. Based on the encouraging results seen in this study, we are initiating a Phase 2 trial to further evaluate the safety and efficacy of PVS-10200 in treating interventions for PAD.”
Pervasis has demonstrated proof-of-concept for this novel cellular approach in two Phase 2 trials with Vascugel®, the Company’s first cellular treatment developed using its proprietary technology platform, in patients with end-stage renal disease receiving arteriovenous (AV) access for hemodialysis. The two studies, known as V-HEALTH, showed that perivascular placement of Vascugel® at the time of AV access creation resulted in higher patency rates, extended time to first intervention and greater lumen diameter at six months. Results also showed that treatment with Vascugel® was safe with fewer thrombic events, early complications and interventions than compared to placebo. Additionally, positive efficacy trends were shown in various other secondary endpoints.
About Peripheral Artery Disease
Peripheral arterial disease (PAD) affects approximately 8 million Americans according to the American Heart Association and is characterized by the build up of fatty deposits on the inner lining of the artery walls. Over time, the build up of fatty deposits restricts blood flow primarily in the arteries leading to the kidneys, arms, legs, stomach and feet. PAD becomes more common as a person ages and by age 65, about 12 to 20 percent of the population has the disease. People with PAD have a four to five times higher risk of heart attack and stroke compared to those who do not have the disease. Treatment often begins with lifestyle changes, including smoking cessation, diet and exercise. Medication is often used along with lifestyle changes to treat PAD. Some patients require additional intervention to help manage the disease and these patients may undergo angioplasty, stent placement or have surgery to help treat the narrowed artery. Restenosis is a large problem for patients following treatment for PAD and to date, drugs have had limited success in treating restenosis.
About PVS-10200
PVS-10200 is a minimally invasive cell therapy currently being developed by Pervasis to treat interventions for PAD and other vascular applications. The Company’s proprietary technology platform harnesses the power of the endothelium to promote natural healing to repair and restore vascular function following an intervention, such as angioplasty, stent placement, peripheral and coronary bypass, and AV access placement for patients with end-stage renal disease. By supplementing the existing endothelium, PVS-10200, an allogeneic endothelial cell treatment, may regulate the inflammatory response and promote natural healing in the vasculature. PVS-10200 may represent a therapeutic advance in treating any vascular intervention and has the potential to become an off-the-shelf, standard-of-care treatment.
About Pervasis Therapeutics, Inc.
Pervasis Therapeutics, Inc. is a clinical-stage cell-based biotechnology company pioneering biologically active products to treat vascular and other serious diseases. The Company has developed a novel, allogeneic endothelial cell therapy that repairs and restores vascular function after injury by mimicking the body’s natural healing process. Pervasis believes its proprietary cell therapy may become the standard of care to promote natural healing following any vascular intervention. Pervasis is also exploring broader indications for its groundbreaking technology in non-vascular applications, such as bone and joint repair, wound healing and inflammation. Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, and Highland Capital Partners. For more information, please visit www.pervasistx.com.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active cellular therapies to treat vascular and other serious diseases, today announced new preclinical data for the Company’s minimally invasive cell therapy, PVS-10200. Results from the preclinical study found that treatment with PVS-10200 (tissue engineered allogeneic endothelial cells) following an intervention for peripheral arterial disease (PAD) resulted in a statistically significant increased lumen area, reduced intimal area, and decreased occlusion compared to control. These data were presented in an oral presentation today at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions in Barcelona, Spain.
In this preclinical study, researchers evaluated treatment with ultrasound-guided percutaneous (needle delivered) administration of PVS-10200 to the outside of porcine (pig) femoral arteries immediately following angioplasty and stent placement. Animals in the control group received angioplasty and stents with no further treatment (sham standard of care control). A third group was treated with injection of matrix alone. A total of 36 femoral arteries were evaluated in the study and evaluations were conducted at 30 and 90 days following treatment. At 90 days, PVS-10200 treated arteries had significantly decreased intimal area (3.3 ± 0.4 mm²) compared to control (6.2 ± 0.5 mm², P<0.05) and increased lumen area (20.4 ± 0.7 mm²) compared to control (16.1 ± 0.9 mm² P<0.05). After 90 days, PVS-10200 treated arteries had a 50 percent decrease in percent occlusion compared to sham control (P<0.05). Treatment with the gelatin matrix alone did not differ significantly from the sham control.
“Restenosis, or narrowing of the arteries, following procedural treatment for PAD occurs frequently and is associated with a number of vascular complications and re-interventions,” added Helen M. Nugent, Ph.D., co-founder and vice president, research and development at Pervasis and co-author of the study. “PVS-10200 provides endothelial-based factors to the injured artery, which regulates the inflammatory response within the blood vessel and promotes natural healing. Results from this study indicate that PVS-10200 may offer a novel therapeutic option that can effectively reduce the intimal area and reduce occlusion, and therefore limit restenosis following treatment for PAD.”
“We are pleased to present this compelling preclinical data for PVS-10200,” stated Frederic Chereau, president and chief executive officer of Pervasis Therapeutics. “Treatment with drug-eluting stents has shown no benefit within the peripheral vasculature. There continues to be a significant unmet medical need and a large market potential for new therapies to effectively address common complications related to vascular intervention. Based on the encouraging results seen in this study, we are initiating a Phase 2 trial to further evaluate the safety and efficacy of PVS-10200 in treating interventions for PAD.”
Pervasis has demonstrated proof-of-concept for this novel cellular approach in two Phase 2 trials with Vascugel®, the Company’s first cellular treatment developed using its proprietary technology platform, in patients with end-stage renal disease receiving arteriovenous (AV) access for hemodialysis. The two studies, known as V-HEALTH, showed that perivascular placement of Vascugel® at the time of AV access creation resulted in higher patency rates, extended time to first intervention and greater lumen diameter at six months. Results also showed that treatment with Vascugel® was safe with fewer thrombic events, early complications and interventions than compared to placebo. Additionally, positive efficacy trends were shown in various other secondary endpoints.
About Peripheral Artery Disease
Peripheral arterial disease (PAD) affects approximately 8 million Americans according to the American Heart Association and is characterized by the build up of fatty deposits on the inner lining of the artery walls. Over time, the build up of fatty deposits restricts blood flow primarily in the arteries leading to the kidneys, arms, legs, stomach and feet. PAD becomes more common as a person ages and by age 65, about 12 to 20 percent of the population has the disease. People with PAD have a four to five times higher risk of heart attack and stroke compared to those who do not have the disease. Treatment often begins with lifestyle changes, including smoking cessation, diet and exercise. Medication is often used along with lifestyle changes to treat PAD. Some patients require additional intervention to help manage the disease and these patients may undergo angioplasty, stent placement or have surgery to help treat the narrowed artery. Restenosis is a large problem for patients following treatment for PAD and to date, drugs have had limited success in treating restenosis.
About PVS-10200
PVS-10200 is a minimally invasive cell therapy currently being developed by Pervasis to treat interventions for PAD and other vascular applications. The Company’s proprietary technology platform harnesses the power of the endothelium to promote natural healing to repair and restore vascular function following an intervention, such as angioplasty, stent placement, peripheral and coronary bypass, and AV access placement for patients with end-stage renal disease. By supplementing the existing endothelium, PVS-10200, an allogeneic endothelial cell treatment, may regulate the inflammatory response and promote natural healing in the vasculature. PVS-10200 may represent a therapeutic advance in treating any vascular intervention and has the potential to become an off-the-shelf, standard-of-care treatment.
About Pervasis Therapeutics, Inc.
Pervasis Therapeutics, Inc. is a clinical-stage cell-based biotechnology company pioneering biologically active products to treat vascular and other serious diseases. The Company has developed a novel, allogeneic endothelial cell therapy that repairs and restores vascular function after injury by mimicking the body’s natural healing process. Pervasis believes its proprietary cell therapy may become the standard of care to promote natural healing following any vascular intervention. Pervasis is also exploring broader indications for its groundbreaking technology in non-vascular applications, such as bone and joint repair, wound healing and inflammation. Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, and Highland Capital Partners. For more information, please visit www.pervasistx.com.
Tuesday, May 19, 2009
Peripheral Arterial Disease - Clinically
Peripheral arterial disease is characterized by a gradual reduction in blood to the extremities secondary to atherosclerosis. In diabetes, the pattern of atherosclerotic occlusion typically shows a propensity toward the infrapopliteal vessels. Additionally, impairment of the microcirculation manifests in diminished vasoreactivity and a functional ischemia that is not always correctable with surgery. However, when a nonhealing wound is complicated by peripheral arterial disease, revascularization is paramount to wound healing. Revascularization can be accomplished through traditional bypass surgery or newer endovascular interventions, such as angioplasty and stenting. These less invasive techniques of revascularization offer the advantages of quicker recovery and lower morbidity but durability may be compromised. Ultimately, the choice of revascularization procedure should be based on the clinical characteristics of the atherosclerotic lesion along with the individual patient history.
Monday, May 18, 2009
10 million people in the U.S. suffer from lower-limb peripheral arterial disease
According to iData Research, an international medical device & dental market research firm, an estimated 10 million people in the U.S. suffer from lower-limb Peripheral Arterial Disease (PAD), with less than 20% of these diagnosed by a physician.
As early detection increases and more patients seek treatment, the U.S. market for peripheral vascular treatment will grow to an estimated $4.7 billion by 2015.
PAD is the formation of plaque in arterial blood vessels of the outer circulatory system. This causes damage to the arterial wall, which increases the risk of stroke. In 2008, over 4 million individuals in the U.S. had symptoms indicative of PAD, such as persistent leg cramping, numbness, fatigue and severe pain.
"Of people aged 50 to 69 with a history of smoking or diabetes, approximately 30% will manifest PAD," says Kamran Zamanian PhD., CEO of iData Research, "This will drive sales for PAD treatment devices, particularly for devices such as stents and stent-grafts, and complementary and alternative products, like embolic protection and atherectomy devices."
In 2008, the largest segment in the U.S. market for peripheral vascular devices was for stents, which represented 28.7% of the overall treatment market. The stent market will grow at double digit rates through 2015, led by an increase in early diagnoses. The U.S. government and the medical community have taken an active role in improving awareness of PAD among physicians and the general population.
iData Research provides market intelligence reports on the peripheral vascular device market, for the U.S., Europe and Japan. Watch the iData movie at: www.idataresearch.net/discoveridata.html
http://www.idataresearch.net/
As early detection increases and more patients seek treatment, the U.S. market for peripheral vascular treatment will grow to an estimated $4.7 billion by 2015.
PAD is the formation of plaque in arterial blood vessels of the outer circulatory system. This causes damage to the arterial wall, which increases the risk of stroke. In 2008, over 4 million individuals in the U.S. had symptoms indicative of PAD, such as persistent leg cramping, numbness, fatigue and severe pain.
"Of people aged 50 to 69 with a history of smoking or diabetes, approximately 30% will manifest PAD," says Kamran Zamanian PhD., CEO of iData Research, "This will drive sales for PAD treatment devices, particularly for devices such as stents and stent-grafts, and complementary and alternative products, like embolic protection and atherectomy devices."
In 2008, the largest segment in the U.S. market for peripheral vascular devices was for stents, which represented 28.7% of the overall treatment market. The stent market will grow at double digit rates through 2015, led by an increase in early diagnoses. The U.S. government and the medical community have taken an active role in improving awareness of PAD among physicians and the general population.
iData Research provides market intelligence reports on the peripheral vascular device market, for the U.S., Europe and Japan. Watch the iData movie at: www.idataresearch.net/discoveridata.html
http://www.idataresearch.net/
Subscribe to:
Posts (Atom)
Posts
